Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06997081 · ClinicalTrials.gov registry record · Phase 2
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT06997081: Recruiting Phase 2 study of Multiple Myeloma, sponsored by University of Miami.
NCT06997081 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 104 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06997081, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.
Primary Outcome
Minimal residual disease (MRD) is defined as 0 residual clonal cells in a bone marrow biopsy sample MRD negativity (10\^-5 sensitivity) after 12 cycles, in participants who have been newly diagnosed with Multiple Myeloma receiving Lenalidomide and Low-Dose Dexamethasone (ERd) combination treatment.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Elranatamab
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2030-09-30 |
| Phase | Phase 2 |
What NCT06997081 shows while recruiting
NCT06997081 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT06997081 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06997081 about?
NCT06997081 is a clinical study titled "ERd Combination Treatment in Newly Diagnosed Multiple Myeloma". The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.
What is the current status of trial NCT06997081?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2025-09-16. Estimated completion is 2030-09-30.
What conditions does trial NCT06997081 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06997081?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Elranatamab (DRUG).
Who is sponsoring clinical trial NCT06997081?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06997081 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06997081's enrollment target sits among peer trials
104 163rd of 438 higher than 276 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI